Home Featured Page 159

Featured

Latest

A Dispatch from APA’s Annual Meeting: Psychedelics Return at an Awkward Moment for American Psychiatry

Momentum Amidst Tumult: The FDA Reshuffle, Approval Timelines, and the Compass-Usona Race

Field Notes #1: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin Approval

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical, and Increasingly Coordinated

Bit Yaden on Preparing the Next Generation of Psychiatrists for a Psychedelic Future

Sep 13, 2022, 16:50 ETMINDCURE Announces Financial Results for Fiscal 2022VANCOUVER,...

Psilera Receives First Patent Allowance for Transdermal Patch Formulations

Revive Therapeutics Announces Submission of Amended Phase 3 COVID-19 Study Protocol...

Mindset Pharma Receives Scientific Advice from UK Regulator Facilitating Advancement of...

Small Pharma Enters Into Automatic Share Purchase Plan

Numinus provides update on acquisition integration and announces new client financing...

Nature Biotechnology Selects Delix Therapeutics as a Leading Biotech Start-Up

PT355 – Ifetayo Harvey – The Drug War, Caregiving, and Blue...

Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke...

Psychedelic Bulletin #118 – San Francisco ‘Decriminalizes’ Psychedelics

EDITOR PICKS

A Dispatch from APA’s Annual Meeting: Psychedelics Return at an Awkward...

Momentum Amidst Tumult: The FDA Reshuffle, Approval Timelines, and the Compass-Usona...

Field Notes #1: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.